24/7 Patient Assistance: 760-405-8205

Joseph Merriman, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated

  • Bio & Insurance Information

    Dr. Joseph Merriman is a specialist in oncology, located in Nashville, Tennessee and works with Vanderbilt University Medical Center. He got his diploma from University of Tennessee College of Medicine and did his residency in Internal Medicine at the University of Utah. He completed his fellowship in Hematology/Oncology at Vanderbilt University and has almost 5 years of practice.


  • Education & Training

    dept_icon

    University of Utah

    Residency

    dept_icon

    Vanderbilt University

    Fellowship

    dept_icon

    University of Tennessee College of Medicine

    Medical School

    dept_icon

    The University of the South Other Training , Biology, Economics

    Sewanee

  • Hospital & Practice

    Vanderbilt University Medical Center

    Languages: English/Spanish

    (615) 322-5000

    1211 Medical Center Dr

    Nashville, Tennessee 37232

    Read More
  • Publications & Memberships

    Dr. Joseph Merriman has contributed to 4 publications.

    Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.

    Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N; Ecancermedicalscience. 2016.

    See more >>

    Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue.

    Wynn D, Merriman J, Patel AB, Hitchcock YJ, Garrido-Laguna I, Renner D, Clardy SL; Clin Neurol Neurosurg. 2016 Oct.

    See more >>

    Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.

    Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Saml...; Cancer Immunol Immunother. 2016 Aug.

    See more >>

    Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma.

    Merriman J, Tward J, Albertson D, Dechet C, Agarwal N; J Immunother. 2016 Feb-Mar.

    See more >>

    Memberships

    American Society of Clinical Oncology